Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective
Abstract Coronavirus disease of 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly the world over. The disease was declared “pandemic” by the World Health Organization. An approved therapy for patients with COVID-19 has yet to emerge; however, there are some medications used in the treatment of SARS-CoV-2 infection globally including hydroxychloroquine, remdesivir, dexamethasone, protease inhibitors, and anti-inflammatory agents. Patients with underlying cardiovascular disease are at increased risk of mortality and morbidity from COVID-19. Moreover, patients with chronic stable states and even otherwise healthy individuals might sustain acute cardiovascular problems due to COVID-19 infection. This article seeks to review the latest evidence with a view to explaining possible pharmacotherapies for the cardiovascular complications of COVID-19 including acute coronary syndrome, heart failure, myocarditis, arrhythmias, and venous thromboembolism, as well as possible interactions between these medications and those currently administered (or under evaluation) in the treatment of COVID-19..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Cardiovascular drugs and therapy - 35(2020), 2 vom: 15. Juli, Seite 249-259 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Talasaz, Azita Hajhossein [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
COVID-19 |
| doi: |
10.1007/s10557-020-07037-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR043609414 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR043609414 | ||
| 003 | DE-627 | ||
| 005 | 20230519193337.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210326s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10557-020-07037-2 |2 doi | |
| 035 | |a (DE-627)SPR043609414 | ||
| 035 | |a (DE-599)SPRs10557-020-07037-2-e | ||
| 035 | |a (SPR)s10557-020-07037-2-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.00 |2 bkl | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Talasaz, Azita Hajhossein |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Coronavirus disease of 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly the world over. The disease was declared “pandemic” by the World Health Organization. An approved therapy for patients with COVID-19 has yet to emerge; however, there are some medications used in the treatment of SARS-CoV-2 infection globally including hydroxychloroquine, remdesivir, dexamethasone, protease inhibitors, and anti-inflammatory agents. Patients with underlying cardiovascular disease are at increased risk of mortality and morbidity from COVID-19. Moreover, patients with chronic stable states and even otherwise healthy individuals might sustain acute cardiovascular problems due to COVID-19 infection. This article seeks to review the latest evidence with a view to explaining possible pharmacotherapies for the cardiovascular complications of COVID-19 including acute coronary syndrome, heart failure, myocarditis, arrhythmias, and venous thromboembolism, as well as possible interactions between these medications and those currently administered (or under evaluation) in the treatment of COVID-19. | ||
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SARS-Cov2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cardiovascular |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pharmacotherapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Venous thromboembolism |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Drug–drug interactions |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Kakavand, Hessam |e verfasserin |4 aut | |
| 700 | 1 | |a Van Tassell, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Aghakouchakzadeh, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Sadeghipour, Parham |e verfasserin |4 aut | |
| 700 | 1 | |a Dunn, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Geraiely, Babak |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular drugs and therapy |d Dordrecht [u.a.] : Springer Science + Business Media B.V, 1987 |g 35(2020), 2 vom: 15. Juli, Seite 249-259 |w (DE-627)SPR011281340 |w (DE-600)2003553-6 |x 1573-7241 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2020 |g number:2 |g day:15 |g month:07 |g pages:249-259 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10557-020-07037-2 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.00 |q ASE |
| 936 | b | k | |a 44.40 |q ASE |
| 951 | |a AR | ||
| 952 | |d 35 |j 2020 |e 2 |b 15 |c 07 |h 249-259 | ||